June 16, 2005 09:06 ET

Hot Stocks to Watch for Thursday, June 16, 2005: Fighting Cancer and Hepatitis!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.

WESTON, FL -- (MARKET WIRE) -- June 16, 2005 -- announces the following stocks to its Hot Stocks List: Novelos Therapeutics, Inc. (OTC BB: NVLT), Boston Scientific Corporation (NYSE: BSX), JDS Uniphase Corporation (NASDAQ: JDSU), RF Micro Devices Inc. (NASDAQ: RFMD).

Novelos Therapeutics, Inc. (OTC BB: NVLT), a biotech company focusing on oxidized glutathione for use in fighting cancer and hepatitis, just announced that it has filed an orphan drug application with the U.S. FDA for the Company's lead compound, NOV-002. The application focuses on the investigation of combination therapy of NOV-002 with standard chemotherapy for treating refractory (chemotherapy resistant) ovarian cancer. A response from the FDA is expected by mid August.

Other stocks highlighted include Boston Scientific Corporation (NYSE: BSX): Hot Stocks List, up 1% on 5 million shares, JDS Uniphase Corporation (NASDAQ: JDSU): Hot Stocks List, down 3% on 32 million shares, RF Micro Devices Inc. (NASDAQ: RFMD): Hot Stocks List, up 4% on 3 million shares.

"Economists have ratcheted back their estimates for the pace of U.S. growth since the March durable goods number came in much lower than expected. The consensus estimate was hovering around 3.6% for GDP, but now they have been scaled down to about the 3% to 3.5% range. Shipments of core capital goods, a measure of business investment, dropped 1.1% in March." More is available at:'s Daily Stock Updates:, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has not been compensated but can receive up to one hundred thousand dollars for NVLT. CRG intends to sell its shares. CRG has sold approximately zero NVLT shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Contact Information

    Charles T. Tamburello
    Capital Research Group Inc